Trial · NCT05230901
Registered outcomes29
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 29
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Extracellular volume (ECV)-derived matrix volume (measured by CMR) | 12 months | Differences between treatment groups in reduction of extracellular volume (ECV)- derived matrix volume (measured by CMR) after 12 months |
| Secondary | Left ventricular ejection fraction | 12 months | Differences in recovery of left ventricular ejection fraction (EF) in % (measured by CMR) after 12 months |
| Secondary | Global longitudinal strain | 12 months | Differences in recovery of global longitudinal strain (GLS) in % (measured by CMR) after 12 months |
| Secondary | diastolic function | 12 months | Differences in recovery of diastolic function (measured by CMR) after 12 months |
| Secondary | Left ventricular myocardial tissue volumes | 12 months | Differences in reduction of left ventricular myocardial tissue volumes (measured by CMR) after 12 months |
| Secondary | Left ventricular blood volumes | 12 months | Differences in reduction of left ventricular blood volumes (measured by CMR) after 12 months |
| Secondary | Kansas City Cardiomyopathy Questionnaire | 12 months | Differences in quality of life changes according to 23-items Kansas City Cardiomyopathy Questionnaire (KCCQ) after 12 months |
| Secondary | NYHA status | 12 months | Differences in NYHA status after 12 months |
| Secondary | 6min-walking test distance (6MWT) | 12 months | Differences in 6min-walking test distance (6MWT; in m) after 12 months |
| Secondary | NT-proBNP-levels | 12 months | Differences in NT-proBNP-levels (in pg/ml) after 12 months |
| Secondary | Heart failure hospitalizations | 12 months | Rate of Heart failure hospitalizations within 12 months |
| Secondary | Total mortality | 12 months | Rate of total mortality within 12 months |
| Secondary | Cardiovascular mortality | 12 months | Rate of Cardiovascular mortality within 12 months |
| Secondary | Biomarker Procollagen type I carboxy-terminal propeptide (PICP) | 12 months | Measurement of PICP in ng/ml |
| Secondary | Biomarker Procollagen III N-terminal propeptid (PIIINP) | 12 months | Measurement of PIIINP in ng/ml |
| Secondary | Ratio of Increased collagen degradation (CITP) vs. matrix metalloproteinase-1 (MMP-1) | 12 months | Measurement of CITP (in ng/l) and MMP-1 (in ng/ml) |
| Secondary | Methylation of Iroquois Homeobox 3 (IRX3) | 12 months | Measurement of Methylation of IRX3 in % |
| Secondary | Methylation of rfGAP With Coiled-Coil, Ankyrin Repeat And PH Domains 3 (ACAP3) | 12 months | Measurement of Methylation of ACAP3 in % |
| Secondary | Methylation of Growth Arrest And DNA Damage Inducible Gamma (GADD45G) | 12 months | Measurement of Methylation of GADD45G in % |
| Secondary | Methylation of Chordin (CHRD) | 12 months | Measurement of Methylation of CHRD in % |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05230901/registered